Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

254 clinical studies listed.

Filters:

Chronic Kidney Diseases

Tundra lists 254 Chronic Kidney Diseases clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT05691257

Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

The purpose of this study is to conduct a a cohort study to evaluate the efficacy and safety of the efficacy and safety of roxadustat for the treatment of anemia, quality of life and cardiac function in patients with heart failure and chronic kidney disease.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-19

Heart Failure
Chronic Kidney Diseases
Anemia
TERMINATED

NCT04500665

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

Gender: All

Ages: 21 Years - 80 Years

Updated: 2026-11-18

1 state

Chronic Kidney Diseases
COMPLETED

NCT03991169

Oral Iron in Children With Chronic Kidney Disease

This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs. no iron therapy arm for 3 months. The outcomes will include muscle strength, physical activity, and changes in eating behavior, which will be measured at enrollment and at the end of the study period.

Gender: All

Ages: 1 Year - 21 Years

Updated: 2026-11-18

2 states

Chronic Kidney Insufficiency
Chronic Kidney Diseases
NOT YET RECRUITING

NCT07805109

Subclinical Renal Dysfunction in Rheumatoid Arthritis

This comparative cross-sectional study aims to determine the prevalence of subclinical renal dysfunction in patients with rheumatoid arthritis and to evaluate its association with disease activity and inflammatory markers compared with age- and sex-matched healthy controls at Assiut University Hospitals.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-17

Rheumatoid Arthritis
Renal Dysfunction
Chronic Kidney Diseases
ACTIVE NOT RECRUITING

NCT04741646

Ferric Citrate and Chronic Kidney Disease in Children

We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20 core clinical sites.

Gender: All

Ages: 6 Years - 18 Years

Updated: 2026-11-16

13 states

Chronic Kidney Diseases
ENROLLING BY INVITATION

NCT05279742

Enhancing the Natriuretic Peptide System in HFpEF

The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies function using drugs Sacubatril/Valsartan (Entresto) and MANP.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-16

1 state

Heart Failure With Preserved Ejection Fraction
Chronic Kidney Diseases
COMPLETED

NCT06071143

Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease

A Single arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients with Chronic Kidney Disease. The aim of this study is to evaluate the safety and preliminary efficacy of KDSTEM Inj. in the treatment in Patients with Chronic Kidney Disease.

Gender: All

Ages: 19 Years - 80 Years

Updated: 2026-11-13

1 state

Chronic Kidney Diseases
RECRUITING

NCT05395247

Geriatric Assessment for Older Kidney Transplantation Candidates

Geriatric assessment is now widely used to decide whether older patients with chronic kidney disease should be put on the kidney transplantation waiting list. This study aims to evaluate the association between Geriatric assessment and inscription on kidney transplantation.

Gender: All

Ages: 65 Years - Any

Updated: 2026-11-12

Chronic Kidney Diseases
NOT YET RECRUITING

NCT07921342

An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care

The goal of this clinical trial is to test whether an individuation intervention can improve the quality of chronic kidney disease (CKD) care for patients with low socioeconomic status (SES) and to understand the mechanisms through which the intervention may improve care delivery and clinical outcomes. The study will involve nephrologists and their patients with CKD, with a focus on reducing healthcare disparities associated with low SES. Researchers will compare nephrologists who receive the individuation intervention with those in the control group to determine whether encouraging physicians to better understand their patients as unique individuals, rather than relying on assumptions associated with socioeconomic status, improves the quality of CKD care for patients with low SES.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-10

1 state

Chronic Kidney Diseases
RECRUITING

NCT07391267

Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can slow or prevent this progression. NAFLD and CKD frequently coexist due to shared mechanisms such as insulin resistance, inflammation, oxidative stress, dyslipidemia, and metabolic syndrome. Because of these overlapping pathways, a single therapy targeting both organs may offer major benefits. Semaglutide is known to reduce liver fat, improve inflammation and fibrosis, promote weight loss, and provide renal protection. This project will test whether adding oral semaglutide to standard care leads to better kidney and liver outcomes than standard care alone. The study is designed as a randomised controlled trial conducted at ILBS, enrolling adults having NAFLD with CKD (with specific eGFR and albuminuria criteria). Participants will be followed for 2 years, with regular assessment of kidney function (eGFR, ACR), liver health (FibroScan, ALT/AST), metabolic parameters, and cardiovascular outcomes. A parallel animal study in mice with diet-induced fatty liver disease will validate mechanistic findings through liver and kidney histology, gene expression, metabolic tests, and biochemical markers after semaglutide treatment. Expected outcome: To demonstrate that semaglutide slows CKD progression and improves NAFLD, supporting its use as a therapeutic option for patients with coexisting both conditions.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-09

1 state

Chronic Kidney Diseases
MAFLD
RECRUITING

NCT06981585

Physical Impairments in Children With Chronic Renal Failure

When the literature is examined, it is seen that the extent to which cough strength, grip strength, physical activity level and quality of life levels are affected in children with chronic kidney failure compared to healthy children is not sufficiently clarified. For this reason, this study aimed to reveal impairments in grip strength, cough strength, physical activity, sleep quality or quality of life in children with chronic renal failure compared to healthy children.

Gender: All

Ages: 8 Years - 18 Years

Updated: 2026-11-05

Chronic Kidney Failure
Chronic Kidney Diseases
NOT YET RECRUITING

NCT07770633

Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty

This study is a single-center, prospective, randomized, open-label clinical trial evaluating three commercially available closed-incision negative pressure wound therapy (ciNPWT) devices: NPseal, PICO, and Prevena, in adult patients undergoing primary total knee arthroplasty (TKA) who meet predefined high-risk criteria for wound complications. A total of approximately 300 participants will be enrolled and randomized in a 1:1:1 fashion to receive one of the three study dressings applied over the closed surgical incision at the end of the procedure. All participants will otherwise receive standard perioperative and postoperative care. The primary follow-up period will extend through 90 days after surgery. The primary objective is to compare the incidence of 90-day surgical site complications, including superficial infection, wound dehiscence, seroma, and hematoma, across the three dressing groups. Secondary objectives include evaluation of device usability, patient experience, and device-related issues (such as loss of seal, alarms, tubing or pump problems, fluid saturation, and premature dressing changes), as well as assessment of the interaction between skin closure method and device performance. Research-specific activities are limited to eligibility confirmation, informed consent, randomization, administration of a brief postoperative patient survey at approximately postoperative day 7 and/or dressing removal, provider assessment of the dressing at removal, and collection of clinical outcomes from the medical record. No additional blood draws, imaging, or invasive procedures are required for participation. This study is designed to address a gap in the literature by providing head-to-head comparative data on commonly used ciNPWT systems in a high-risk primary TKA population, with the goal of informing postoperative wound management strategies in clinical practice.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

Wound Surgical
Diabetes
Obesity
+2
TERMINATED

NCT04968184

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula \[eGFR {EPI}\] ≥15 to ≤44 mL/min/1.73 m\^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and \<180 mm Hg and taking 2 or more antihypertensive medications.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

83 states

Chronic Kidney Diseases
RECRUITING

NCT07868666

Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes

This pilot study will evaluate the feasibility of using a clinical decision support(CDS) message to support consideration of SGLT2 inhibitor prescribing in patients with type 2 diabetes who recently had acute kidney injury. Participating M Health Fairview primary care clinics will be randomized to either receive the clinical decision support intervention or continue usual care. In intervention clinics, providers or clinic pharmacists will receive a message before a scheduled encounter with an eligible patient. The message is intended to support clinical decision-making about SGLT2 inhibitor use, but prescribing decisions will remain with the patient's usual clinical care team. The study will assess feasibility outcomes, including identification of eligible patients, delivery of clinical decision support (CDS) messages, provider/pharmacist receipt of CDS messages, SGLT2i consideration, SGLT2i prescribing, and availability of follow-up kidney function data in the electronic health record.

Gender: All

Ages: 30 Years - 75 Years

Updated: 2026-11-04

1 state

Type 2 Diabetes Mellitus
Acute Kidney Injury
Chronic Kidney Diseases
COMPLETED

NCT04823286

Integrated Patient Care Intradialysis Programme in Hemodialysis Through a Virtual Health Platform

There is wide evidence regarding the weak points of end-stage Chronic kidney disease (CKD) patients in hemodialysis, and they include three intervention aspects: exercise, nutrition and psychological support. Evidence shows that exercise for patients in hemodialysis results in increased survival rate, functional capacity, strength and health-related quality of life. Additionally, different studies have shown the benefits of psychological interventions and the positive effect of educational programs on nutritional care for patients in hemodialysis. Despite the well-known benefits of exercise, this kind of programs are not being implemented in the routine clinical care of hemodialysis patients. Thus, the GoodRENal project aims to promote healthy lifestyles among dialysis patients in a holistic approach that combines exercise, nutrition and psychological wellbeing plus cognitive functioning addressing adult learners. The project will, in phase 1, explore barriers and facilitators of patients, carers and health professionals towards healthy lifestyle (physical activity, nutrition and psychological well being). In phase 2, the project will develop a health virtual platform including these three dimensions of cares. In summary, the project outputs will be: 1. A didactic content in a modular platform to create an educational program for integrated treatments in patients with dialysis 2. A guideline to promote healthy lifestyles among dialysis patients for health care providers 3. A guideline to promote e healthy lifestyles among dialysis patients for patients and formal - nonformal carers

Gender: All

Ages: 18 Years - 99 Years

Updated: 2026-11-02

2 states

End Stage Renal Disease
Hemodialysis-Induced Symptom
Chronic Kidney Diseases
COMPLETED

NCT04099992

Mindfulness in Chronic Kidney Disease

This study will test whether mindfulness meditation (MM) improves sympathetic function in chronic kidney disease (CKD) and whether transcutaneous vagus nerve stimulation (tVNS) optimizes the sympatho-inhibitory effects of mindfulness meditation (MM) and restores autonomic balance in CKD patients.

Gender: All

Ages: 40 Years - 80 Years

Updated: 2026-10-30

1 state

Chronic Kidney Diseases
RECRUITING

NCT06927024

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)

30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-29

1 state

Chronic Kidney Diseases
RECRUITING

NCT04759274

Diuretic Tuner Clinical Decision Support

This purpose of this study is to determine the effectiveness of a mobile phone application in helping to control body swelling in patients with kidney problems. The application will help in the day to day adjustments in diuretic medication dosing. Participants in this study will have an application loaded on to their mobile phone by the study team and be taught how to use it over a 2 hour visit. Participants will need to check their blood pressure and weight daily and enter this information into the mobile phone application every day. Participants will need to follow daily instructions in their medication dosing provided by the application. There will be periodic blood testing. This will happen at 2 weeks, 90 days, and up to 4 other times if necessary. At the end of the study there is a 2 hour study visit during which participants will answer a survey. The total length of the study is 90 days.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-29

1 state

Edema
Hypervolemia
Chronic Kidney Diseases
+1
RECRUITING

NCT06281899

Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus

This is a prospective multicenter randomized controlled trial with a total duration of 36 months aiming to evaluate the effectiveness and the safety of low protein diet on top of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and renin-angiotensin-aldosterone inhibitors (RAASi) in reducing the progression of chronic kidney disease in patients with type 2 Diabetes Mellitus

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-28

Chronic Kidney Diseases
Type 2 Diabetes Mellitus
ACTIVE NOT RECRUITING

NCT07891988

Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention

This research trial will test whether using carbon dioxide as a contrast medium during surgery to open blocked leg arteries can prevent kidney injury. One in five people over 55 in the UK suffer with narrowing or blockages in their leg arteries, which is called peripheral arterial disease. It leads to poor leg circulation, which can cause leg gangrene or infection. Sometimes this may even lead to major lower limb amputation. To prevent this from happening, the affected arteries can be opened using endovascular revascularisation. These procedures are the most common artery surgeries in the NHS. To be able to perform these procedures, doctors use an iodine-based contrast medium (dye) injected in the artery, which can negatively affect kidney function. Instead of the usual dye that causes kidney problems, carbon dioxide can be used as it does not damage the kidneys. No previous randomised controlled trial, however, has tested whether using carbon dioxide via automated injectors does indeed protect the kidneys in these procedures. This research will take place in at least six NHS hospitals in the UK. People with peripheral arterial disease and chronic kidney disease who are having a procedure to open their arteries will be asked to take part. Participants will be randomly chosen to have the procedure with carbon dioxide or with standard iodine-based contrast medium. The investigators will then perform blood tests to measure serum creatinine on the 2nd, 30th, and 90th day after the procedure to compare kidney function between the two groups. The investigators will also compare the volume of iodine-based contrast medium used. The study will also include qualitative research into how the hospital staff performing the intervention feel, as well as how participants found the procedure with carbon dioxide.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-23

1 state

Peripheral Arterial Disease
Chronic Kidney Diseases
Acute Kidney Injury
COMPLETED

NCT05113641

Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD)

Metabolic acidosis is a common problem that occurs with worsening chronic kidney disease. Dietary acid can build up when the kidneys are not working well. This can be associated with a higher risk of worsening kidney function and death. The usual treatment is a medication called sodium bicarbonate which works to balance the acids in the body. The medication however often does not work and causes side effects. Consumption of alkalizing fruit and vegetables may work as a treatment for metabolic acidosis. This trial is being done to see if fruit and vegetables, provided via home delivery, can become a viable management for metabolic acidosis in patients with chronic kidney disease.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-23

2 states

Chronic Kidney Diseases
Metabolic Acidosis
RECRUITING

NCT06593392

Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

Rationale: * People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy. * Difelikefalin is a medicine that can treat the itching related to long term kidney disease. * Clinical studies have shown difelikefalin to reduce itching in adults on haemodialysis, while being safe and tolerable. * The current study is being done in adolescents aged 12 to 17 years on haemodialysis who have moderate to severe itching related to long term kidney disease to assess if difelikefalin is safe in this age group. The aims of the study are: Main aim: To assess the safety of difelikefalin in adolescents who are on haemodialysis and have itching related to long term kidney disease Secondary aim: To measure the amount of difelikefalin that enters the blood in adolescents who are on haemodialysis and have itching related to long term kidney disease Study Design At least 18 adolescents, aged 12 to 17 years, who are on haemodialysis and have itching related to long term kidney disease will take part in this study. All study participants will receive difelikefalin 3 (or up to 4) times weekly for up to 12 weeks. The study duration for a participant is up to 17 to 18 weeks; during this period, participants will visit the clinic 3 times weekly (during their haemodialysis visits).

Gender: All

Ages: 12 Years - 18 Years

Updated: 2026-10-23

Pruritus
Chronic Kidney Diseases
COMPLETED

NCT02076256

Helping Relationships From Significant Others on Healthy Lifestyle and Quality of Life Among Patients With CKD( CKD Lifestyle)

This clinical trial aims to evaluate the effectiveness of a helping relationships intervention program for patients with chronic kidney disease (CKD). The study investigates whether support and involvement from significant others can assist CKD patients in adopting and maintaining health-promoting behaviors, thereby potentially delaying disease progression. A total of 120 CKD patients will be enrolled and randomly assigned to either an experimental group or a control group. The experimental group will receive the helping relationships intervention program, while the control group will receive routine nursing care. The primary objective is to assess the impact of this intervention on patients' healthy lifestyles, stages of behavior change, and overall quality of life over a 12-month follow-up period.

Gender: All

Ages: 20 Years - Any

Updated: 2026-10-23

Chronic Kidney Diseases
NOT YET RECRUITING

NCT07072767

Technology-enabled Social Network Intervention to Increase Live Donor Kidney Transplantation

The study is a 2-arm randomized controlled trial among patients referred for kidney transplant evaluation at a single transplant center to compare the effects of a digital-analog intervention to increase living-donor kidney transplant access (KT-CONNECT) versus usual care. Following consent and baseline assessment, participants are randomized with equal allocation to 2 treatment arms: the KT-CONNECT intervention or Usual Care

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-20

1 state

End-Stage Renal Disease
Chronic Kidney Diseases
Kidney Transplant
+1